Assessing Methotrexate Adherence in Rheumatoid Arthritis: A Cross-Sectional Survey by unknown
ORIGINAL RESEARCH
Assessing Methotrexate Adherence in Rheumatoid
Arthritis: A Cross-Sectional Survey
Dana B. DiBenedetti . Xiaolei Zhou . Maria Reynolds . Sarika Ogale .
Jennie H. Best
Received: March 24, 2015 / Published online: May 13, 2015
 The Author(s) 2015. This article is published with open access at Springerlink.com
ABSTRACT
Introduction: Limited data are available to
explain nonadherence to methotrexate (MTX)
therapy in patients with rheumatoid arthritis
(RA). Better understanding of patterns of MTX
use and reasons for nonadherence may help
identify patients who would benefit from
alternative RA treatments and potentially aid
in developing strategies to increase overall
adherence. The purpose of this study was to
assess patients’ self-reported adherence to MTX
and to identify reasons for nonadherence.
Methods: Patient panel members in the US
self-reporting a diagnosis of RA of C3 months’
and current MTX use of C4 weeks’ duration,
with or without concomitant use of another RA
prescription medication, participated in this
cross-sectional, web-based survey.
Results: The sample population (251 MTX
monotherapy, 250 MTX combination
therapy) was predominantly female, white,
non-Hispanic, and educated; 48% were
18–44 years-old, 47% had medical
comorbidities, 66% were first diagnosed with
RA B5 years earlier, 51% reported MTX use of
\1 year, and 83% reported oral MTX use.
Forty-two percent reported not taking MTX
exactly as prescribed. Reasons for
nonadherence included forgetting to take it
(33%), not needing it when feeling well (24%),
and concern about long-term safety (24%).
Among nonadherent patients, 53% took
smaller doses, 52% skipped doses, and 6%
reported other nonprescribed ways of taking
MTX. Younger age, male sex, and shorter
duration of MTX use were associated with
poorer self-reported adherence. Compared
with monotherapy patients, combination
therapy patients, particularly those taking C2
other RA prescriptions, were less likely to report
high adherence.
Conclusion: Nearly half the sample reported
poor MTX adherence because they forgot to
take it, thought it was not needed when they
felt well, or had long-term safety concerns.
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Patients taking C2 other RA prescription
medications were less likely to report good
adherence. Reducing treatment burden
without sacrificing efficacy may be a strategy
worth evaluating.
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INTRODUCTION
Rheumatoid arthritis (RA) is a chronic
autoimmune disease characterized by
inflammation of the membrane lining the
joints (the synovium). Patients with RA may
experience pain, redness, swelling, stiffness,
and restricted movement around the joints of
the hands, feet, elbows, knees, and neck that
lead to loss of function, deformity, and
disability.
Approximately 1.5 million people in the US,
or 0.6% of the population, have RA [1]. RA
occurs 2–3 times more frequently in women
than in men [2]. Although RA can affect people
at any age, including children, onset usually
occurs between 40 and 60 years of age [3].
Current treatment options include
medication, reduction of joint stress,
occupational and physical therapy, and, in
some cases, surgery. Pharmacologic treatments
for RA generally fall into one of the three drug
categories: nonsteroidal anti-inflammatory
drugs (NSAIDs), corticosteroids, and
disease-modifying antirheumatic drugs
(DMARDs). Although the first two classes
generally have a short onset of action, clinical
response with DMARDs can take weeks to
months [4]. Rheumatologists often use short
courses of corticosteroids for acute flares of RA
or as a bridge between other DMARDS, but the
use of these drugs in RA is controversial [5].
Although both NSAIDs and DMARDs help
alleviate active RA symptoms, only DMARDs
alter the progression of RA.
Worldwide, methotrexate (MTX) is a
common first-line DMARD treatment for
patients with RA. Early initiation of MTX in
patients with RA helps manage joint destruction
and slows disease progression [6], and most
patients who are prescribed MTX are still taking
it after 5 years [7]. In patients with partial
responses to MTX, additional treatments are
often added. MTX can be combined safely with
almost all other DMARDs approved for RA [4].
Although the long-term efficacy, tolerability,
and safety of MTX have been well documented
[6], the clinical response to MTX treatment and
the frequency of adverse events from the drug
may impact patient adherence. Patient
adherence can be influenced by duration of
disease, disease activity, and medical
comorbidities [8]. Better understanding of
patterns of MTX use (as monotherapy and in
combination therapy), patient and disease
characteristics, adherence, and reasons for
nonadherence may help in identifying
patients who would benefit from alternative
RA treatments and in devising strategies to
increase overall patient adherence. Thus, the
primary objectives of this study were to assess
patients’ self-reported adherence to MTX and to
identify reasons for nonadherence.
METHODS
Study Design
The current study was a cross-sectional,
web-based survey in the US of patients self-
reporting a clinician-administered diagnosis of
RA and current treatment with MTX, with or
without concomitant use of another
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prescription medication for RA. Participants
were recruited from an existing opt-in online
panel of patients with RA in the US developed
and maintained by All Global [9], a leading data
collection agency focused solely on health care
research that specializes in hard-to-reach
populations and maintains access to persons
who have been prescreened for specific
characteristics or medical conditions, such as
RA. Respondents were selected from the panel
at random. In the current study, once panel
members logged into their all global accounts,
they were directed to the survey to complete a
few screening questions. Participants meeting
eligibility criteria then reviewed and
electronically provided informed consent
before completing the online questionnaire.
This research was conducted in compliance
with the Declaration of Helsinki. All eligible
respondents received $2 for completing the
survey. The current study was fielded from
September 27, 2013 to October 9, 2013
following RTI International’s ethics committee
approval.
The web-based questionnaire was self-
administered. Participants were encouraged to
complete the questionnaire in a timely manner.
Once they started the questionnaire, they were
able to stop at any point and then resume it
from that point. Participants who completed
the questionnaire were not allowed to access
the survey again.
Study Population
The survey participants were adults who met all
the following criteria: self-reported physician
diagnosis of RA, diagnosis of RA for at least
3 months, current use of MTX for at least
4 weeks, and ability to read and understand
English and provide informed consent.
Eligible participants were classified into one
of two groups based on their current MTX use:
MTX monotherapy, currently taking MTX
without any other prescription medications for
RA; MTX combination therapy, currently taking
MTX and at least one other prescription
medication for RA. The target sample size for
survey completion was 500 participants (250
per MTX group).
Questionnaire Content
The survey questionnaire assessed the following
areas:
• demographic characteristics and health
insurance information;
• current use of MTX and other prescription
medications for RA;
• formulation, frequency of use, and dose of
MTX;
• MTX adherence and reasons for
nonadherence;
• satisfaction with MTX treatment;
• general health, including as assessed by the
Modified Health Assessment Questionnaire
(MHAQ). The eight-item MHAQ [10, 11]
assesses disease-related disability,
discomfort, and quality of life in patients
with RA. Each item is scored from 0 (without
any difficulty) to 3 (unable to do). The total
score is the sum of the scores from the 8
items divided by 8. The total MHAQ score
ranges between 0.0 and 3.0, with higher
scores indicating greater overall disability.
MHAQ scores \0.3 are considered normal,
though the average MHAQ score in the
general population increases with the
participant’s age.
With the exception of the MHAQ, all
questionnaire items were developed
specifically for this study to address study-
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related objectives. Completion time was
approximately 10 min.
Data Analysis
Data analysis was primarily descriptive and
included tables summarizing the demographic
and clinical characteristics of the sample. In
addition, participants’ responses to each of the
survey questions, as well as the derived MHAQ
total score, were summarized by MTX group
(monotherapy or combination therapy) and for
the overall sample. Descriptive statistics (e.g.,
mean, standard deviation, range) for
continuous variables and frequencies with
percentages for categorical variables are
reported. For each question, missing data
(\1%) were excluded from analysis, and no
imputation was performed.
Patient adherence was assessed by the
question, ‘‘During the past 4 weeks, how
much of the time did you take your
methotrexate exactly as prescribed by your
doctor?’’ Patients were able to select ‘‘none of
the time,’’ ‘‘a little of the time,’’ ‘‘some of the
time,’’ ‘‘most of the time,’’ or ‘‘all of the
time.’’Patients who selected ‘‘most’’ or ‘‘all’’ of
the time were classified as showing high
adherence, and those who selected ‘‘none,’’ ‘‘a
little,’’ or ‘‘some’’ of the time were classified as
showing low adherence. A logistic regression
model was also used to identify factors
associated with level of adherence to MTX.
The backward selection method was used to
eliminate nonsignificant variables (P[0.05).
The full model included age, sex, level of
education, race/ethnicity, type of health
insurance, prescription drug coverage,
duration of RA, duration of MTX use, dose of
MTX, satisfaction with MTX, MHAQ total
score, number of other prescription
medications for RA, and number of medical
comorbidities. Analyses were performed using
SAS software, Version 9.3 (SAS Institute Inc.,
Cary, NC, USA).
RESULTS
The screening portion of the survey
questionnaire was completed by 3,849 RA
panelists. In total, 596 participants (15%)
met all eligibility criteria and were classified
into 1 of the MTX groups. Of the 512 eligible
participants who provided informed consent,
501 completed the questionnaire (251 in the
MTX monotherapy group, 250 in the MTX
combination therapy group; Fig. 1). Figure 1
depicts the passage of participants from
screening to enrollment.
Demographics and Medical Comorbidities
Overall, study participants were predominantly
female (62%), white (71%), and non-Hispanic
(84%); 79% reported at least some college
education. Nearly half the study participants
(48%) were 18–44 years of age, and 30% were
45–54 years of age (Table 1). Nearly half (47%)
reported 1 or more of the medical comorbidities
assessed (Table 2), and nearly one quarter (23%)
reported diabetes; 22% reported a MHAQ total
score\0.3, which suggests no disability.
Respondents reported taking a mean of 5
(median, 3) unique prescription medications
(including MTX) for any condition in a typical
week. Of the participants reporting MTX
combination therapy (n = 250), prednisone
was the most commonly reported RA
medication used in addition to MTX, followed
by adalimumab, hydroxychloroquine, and
etanercept. Table 1 presents additional details
on the sample’s RA medication use.
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Patterns of Methotrexate Use
Two-thirds of the overall sample (66%) received
the diagnosis of RA within the past 5 years, and
only 14% received the diagnosis 10 or more
years ago. Slightly more than half the sample
(51%) reported using MTX for less than 1 year,
and 33% reported using it for 1–5 years.
Most respondents (83%) reported using the
oral formulation of MTX; no differences in
formulation were reported between the MTX
monotherapy group (83%) and the
combination therapy group (84%). More than
half (59%) self-reported that their prescriptions
called for them to take MTX orally or to inject it
once a week, twice a week (37%), or ‘‘other’’
(5%) (percentages exceed 100% due to
rounding).
Methotrexate Adherence
Forty-two percent of the overall sample
indicated that they did not take MTX exactly
as prescribed by their doctors at all times during
the past 4 weeks (Table 3).
Of the 211 respondents who indicated that
they did not always take MTX exactly as










- Not currently 
  taking MTX (n = 1628)
- No combination on 
  RA diagnosis for 
  ≥3 months (n = 1514)
- Not taking MTX 
  ≥4 weeks (n = 55)
- Other (n = 56) 
No consent
n = 38
















Fig. 1 Study enrollment. Initially, 596 patients met initial
eligibility criteria. However, only 550 patients (512 ? 38)
were asked for consent. The remaining 46 patients were not
asked for consent because the target sample size for that
treatment group (monotherapy or combination therapy)
had been reached (quota met). Before group quotas were
met, 93% (512/550) of the patients provided informed
consent.MTX methotrexate, RA rheumatoid arthritis
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Table 1 Demographic characteristics by MTX treatment group







18–35 78 (31) 50 (20) 128 (26)
36–44 61 (24) 51 (20) 112 (22)
45–54 67 (27) 81 (32) 148 (30)
55–64 44 (18) 63 (25) 107 (21)
65–75 0 5 (2) 5 (1)
76 and older 1 (\1) 0 1 (\1)
Sex
Male 108 (43) 84 (34) 192 (38)
Female 143 (57) 166 (66) 309 (62)
Education
Less than high school graduate 4 (2) 2 (1) 6 (1)
High school graduate 53 (21) 48 (19) 101 (20)
Some college, technical training/licensure 69 (27) 87 (35) 156 (31)
College graduate 97 (39) 73 (29) 170 (34)
Advanced or professional degree 28 (11) 40 (16) 68 (14)
Hispanic, Latino, or Spanish origin or descent
Yes 31 (12) 50 (20) 81 (16)
No 220 (88) 200 (80) 420 (84)
Race
White 175 (70) 180 (72) 355 (71)
Black/African American 43 (17) 44 (18) 87 (17)
American Indian or Alaska native 3 (1) 6 (2) 9 (2)
Asian 18 (7) 9 (4) 27 (5)
Native Hawaiian or other Paciﬁc Islander 1 (\1) 0 1 (\1)
Other 11 (4) 10 (4) 21 (4)
No answer 0 1 1
Other medications for RA
Prednisone – 82 (33) –
Adalimumab (Humira) – 66 (26) –
Hydroxychloroquine (Plaquenil) – 52 (21) –
Etanercept (Enbrel) – 51 (20) –
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commonly reported reasons were forgetting to
take it, feeling it was not needed when they felt
well, and concern about the long-term safety of
MTX (Fig. 2). Forgetting to take MTX as
prescribed was more frequently reported in
MTX combination therapy (40%) than MTX
monotherapy (27%) respondents (Pearson Chi-
square test, P = 0.0361). Taking ‘‘too many
other medications’’ was reported more
frequently in the MTX combination group
than the MTX monotherapy group (17 vs. 7%;
P = 0.0362).
Additionally, more than half the 211
respondents who indicated that they did not
always take their MTX exactly as prescribed by
their doctors reported that they took smaller
doses than prescribed (53%) or skipped doses
(52%), with similar patterns across MTX groups.
A logistic regression model was used to
identify factors associated with level of MTX
adherence (most or all of the time vs. none to
some of the time). As shown in Fig. 3, results
indicated that younger age, male sex, and
shorter duration of MTX use were associated
with poorer self-reported MTX adherence.
Additionally, compared with MTX
monotherapy patients, MTX combination
therapy patients, particularly those taking C2
other prescription medications for RA, were less
likely to report ‘‘high’’ adherence (odds ratio
[OR], 0.46; 95% confidence interval [CI],
0.25–0.85).
High level of satisfaction was associated with
high level of adherence. Compared with the OR
in patients who described themselves as
‘‘neither satisfied nor dissatisfied,’’ the OR of
high level of adherence was 4.02 (95% CI
1.90–8.51) in patients who were ‘‘very
satisfied’’ and 3.00 (95% CI, 1.51–5.98) in
patients who were ‘‘somewhat satisfied.’’
Education, race/ethnicity, health insurance,
prescription drug coverage, time since RA
Table 1 continued






Inﬂiximab (Remicade) – 29 (12) –
Azathioprine (Azasan, Imuran) – 24 (10) –
Tocilizumab (Actemra) – 23 (9) –
Certolizumab pegol (Cimzia) – 23 (9) –
Sulfasalazine (Azulﬁdine) – 20 (8) –
Leﬂunomide (Arava) – 18 (7) –
Abatacept (Orencia) – 16 (6) –
Tofacitinib (Xeljanz) – 15 (6) –
Anakinra (Kineret) – 14 (6) –
Rituximab (Rituxan) – 13 (5) –
Other – 11 (4) –
Golimumab (Simponi) – 7 (3) –
MTX methotrexate, RA rheumatoid arthritis
The sum of the percentages exceeds 100% because respondents were allowed to select more than 1 response
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diagnosis, MTX dose, MHAQ total score, and
number of medical comorbidities were not
associated with MTX adherence level.
DISCUSSION
The primary objective of this cross-sectional,
web-based survey study was to gain better
understanding of adherence to MTX therapy
and reasons for nonadherence. Better
understanding of the profile of adherence and
reasons for nonadherence may help identify
strategies that can improve patient adherence
and, ultimately, disease management.
In the current study, more than half the
survey respondents were relatively ‘‘new’’ MTX
users (less than 1 year), and 84% had been using
MTX for fewer than 5 years. Although the
sample size for those reporting MTX use of
5 years or more was relatively small, a larger
percentage of MTX combination therapy than
monotherapy patients reported longer-term use
(5 years or more). This finding is not surprising
given that most patients who are prescribed
MTX are still taking it after 5 years, and
additional treatments are often added for
patients with partial responses to MTX [4].
Patients likely have to be taking MTX for some
time with limited success before another
medication is added.
Nearly half the patients in the current study
reported less than perfect adherence to MTX;
similar results were seen across MTX groups.
The most frequently reported reasons for
nonadherence to MTX included forgetting or
not remembering to take it, thinking it was not
needed when they felt well, and concern about
the long-term safety of MTX. More than half the







Diagnosed medical comorbidities, n (%)a
Heart disease 17 (7) 30 (12) 47 (9)
Diabetes 47 (19) 66 (26) 113 (23)
Chronic pulmonary disease 13 (5) 21 (8) 34 (7)
Ulcer 22 (9) 33 (13) 55 (11)
Liver disease 9 (4) 20 (8) 29 (6)
Skin cancer or melanoma 6 (2) 19 (8) 25 (5)
Other autoimmune disease 16 (6) 36 (14) 52 (10)
Other types of cancer 4 (2) 12 (5) 16 (3)
None of the above 156 (62) 108 (43) 264 (53)
MHAQ total scoreb
Mean (SD) 0.8 (0.5) 0.8 (0.5) 0.8 (0.5)
\0.3, n (%) 57 (23) 52 (21) 109 (22)
MHAQ Modiﬁed Health Assessment Questionnaire, MTX methotrexate, SD standard deviation
a The sum of the percentages exceeds 100% because respondents were allowed to select more than 1 response
b MHAQ total score\0.3 suggests no disability
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Table 3 Adherence to MTX by MTX treatment group






Frequency of taking MTX exactly as prescribed
None of the time 3 (1) 0 3 (1)
A little of the time 21 (8) 26 (10) 47 (9)
Some of the time 26 (10) 28 (11) 54 (11)
Most of the time 59 (24) 48 (19) 107 (21)
All of the time 142 (57) 147 (59) 289 (58)
No answer 0 1 1
Ways in which MTX was taken differently than prescribeda
Total 109 102 211
I took smaller doses than prescribed 57 (52) 54 (53) 111 (53)
I skipped doses 54 (50) 56 (55) 110 (52)
Other 6 (6) 7 (7) 13 (6)
No answer 0 0 0
MTX methotrexate










































































Fig. 2 Reasons for nonadherence. Percentages on the bars are based on the sample of patients (n = 211) who indicated that
they did not always take their methotrexate exactly as prescribed by their doctors
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nonadherent patients reported that they took
smaller doses than prescribed, skipped doses, or
did both. Patients’ self-reporting of
nonadherence is generally not a perfect
measure and can be considered a limitation of
this study.
More patients reporting that they forgot to
take MTX were in the combination therapy
group than in the MTX monotherapy group.
Forgetting to take MTX as directed may be
associated with the fact that combination
therapy respondents were slightly older, took
more unique medications per week, and
reported more comorbidities than MTX
monotherapy respondents. Additionally,
logistic regression model results indicate that
patients with two or more other prescription
medications for RA were less likely to report
good adherence than those who used MTX
monotherapy. Other factors associated with
poor adherence include younger age, male sex,
and shorter duration of MTX therapy.
Although the current study adds to the
existing literature on reasons for MTX
nonadherence in patients with RA, several
study limitations should be noted. Despite the
large sample size used, the overall sample was
predominantly female, white, non-Hispanic,
educated, insured, and generally not disabled.
Thus, it is not known how generalizable these
findings are to the broader MTX population,
particularly those who are less educated, sicker,
and perhaps more disabled or more vulnerable
(e.g., those of lower socioeconomic status).
Efforts to include these populations in future
studies, such as in paper- and/or telephone-
administered surveys or recruitment through
clinics, may aid in better understanding
adherence in these patient populations.
Additionally, the participants recruited for this
study came from a convenience sample of an
existing RA panel who agreed to take health-
related surveys as part of their panel












3 mo to <1 y (ref: 4 wk to <3 y)
1 y to <5 y
≥5 y
Very satisfied (ref: neither)
Somewhat satisfied
1 other Rx for RA (ref: none)
≥2 other Rx for RA
Female (ref: Male)


















Fig. 3 Factors related to adherence level (high [n = 396]
vs. low [n = 104]). Results from the logistic regression
analysis with backward selection to remove nonsigniﬁcant
variables (P[0.05) or for ‘‘somewhat’’ or ‘‘very dissatisﬁed’’
are not reported because of the small sample size. CI
conﬁdence interval, MTX methotrexate, OR odds ratio,
RA rheumatoid arthritis, ref reference, Rx therapy
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unknown whether, such panel participants are
generally more motivated and more likely to be
adherent than nonpanel members. How
representative this sample is of the broader RA
population is also unknown. Panel participants
also self-reported their diagnoses of RA. It is
unknown whether any differences in adherence
and reasons for nonadherence would be
demonstrated in a study in participants with
clinician-confirmed diagnoses of RA.
Furthermore, there may be additional reasons
for MTX nonadherence that were not assessed
in the current study (e.g., lack of transportation
to obtain it). The most common reasons for
nonadherence were generated from the
literature and in collaboration with the study
sponsor, but it is possible that other reasons
factor into patient nonadherence and may be
identified in future studies. Finally, the survey
questionnaire did not assess more detailed MTX
treatment patterns, such as time from initiation
of MTX to initiation of another DMARD, length
of MTX discontinuation and reasons for
restarting MTX, and ways in which specific
side effects may affect adherence; these could
help elucidate reasons for nonadherence.
This study has several strengths. The first is
its large sample size, including both
monotherapy and combination therapy
patients, which adds to confidence in the
findings. Another is that identifying specific
reasons for nonadherence and MTX practices in
noncompliant patients (e.g., smaller doses,
skipping doses) suggests that patient education
on proper MTX use and monitoring is critical.
Finally, identifying factors associated with MTX
nonadherence (younger age, male sex, shorter
duration of MTX therapy, taking two or more
other RA prescription medications) suggests it
may be beneficial to develop strategies to help
patients remember to take their MTX. Results
also suggest that reducing treatment burden
(e.g., number of RA prescriptions) without
sacrificing efficacy may be a strategy worth
evaluating in future research.
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